TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06003842

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: Stretching exercises for flexion, extension, lateral flexion and rotation, upper trapezius, levator scapula and pectoralis major muscles will be applied in the maximum range of motion of the cervical region in three planes. To increase the mobility of the thoracic region, exercises for thoracic mobility will be given. Strengthening exercises will focus on the back muscles. The resistance of the exercises will be determined according to the individual capacities and strain levels of the participants, and it will be requested to increase the amount of resistance applied depending on the functional developments. You will be asked to perform the exercises twice a day, with 10 repetitions, for 6 weeks. Participants will be asked to hold the position for 3-5 seconds and return to the starting position while doing the strengthening exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: Stretching exercises for flexion, extension, lateral flexion and rotation, upper trapezius, levator scapula and pectoralis major muscles will be applied in the maximum range of motion of the cervical region in three planes. To increase the mobility of the thoracic region, exercises for thoracic mobility will be given. Strengthening exercises will focus on the back muscles. The resistance of the exercises will be determined according to the individual capacities and strain levels of the participants, and it will be requested to increase the amount of resistance applied depending on the functional developments. You will be asked to perform the exercises twice a day, with 10 repetitions, for 6 weeks. Participants will be asked to hold the position for 3-5 seconds and return to the starting position while doing the strengthening exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: taping
Description: After the Kinesio® Tex application, it will remain in the body for 4 days, and then it will be applied 6 times in total, with a 3-day break. It will be stated that the area to be banded should not contain substances such as cream, hair or oil. Upper Trapeze taping will be performed by applying one end of the Y tape to the upper trapeze and the other end to the lower part of the spina scapula, by affixing the tape to the head of the shoulder while standing upright, and keeping the participant's ear tilted towards the other ear as much as possible. Before attaching the rest of the tape, the participant will be asked to bring the shoulder blades closer together and stand upright. In this position, using a mechanical correction technique along the medial line of the scapula along the spine, the rest of the tape will be adhered as an I tape with 35-50% tension.
Study: NCT06331390

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: niacinamide cosmetic product
Description: immortella skincare product
Study: NCT05782803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercises Group
Description: A Pressure Biofeedback Device will be used in CCF training to increase awareness and focus on the desired muscle. After the person is brought to the hook position, the pressurized biofeedback device will be placed in the middle position between the craniocervical and cervical vertebrae or horizontally so that the protrusion between the earlobe and the chin is removed. It is inflated to a standard 20 mmHg to ensure surface-to-longitudinal contact. Participants are taught the correct craniocervical flexion movement without first working the superficial muscles. The patient is then asked to look with their eyes slightly toward the chest cavity. During the exercises, starting from 20 mmHg and increasing by 2 mmHg, the desired level of 30 mmHg will be reached. At each level, the movement is continued for 10 seconds, resting for 3-5 seconds, 10 repetitions are required. If the same level is maintained for 10 seconds and 10 repetitions, the next level is passed.
Study: NCT05222165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infigratinib
Description: Hard gelatin capsules for oral use
Study: NCT06325891

Intervention type: DIAGNOSTIC_TEST
Intervention: Gastric mucosal brushing
Description: Gastric mucosal brushing will be performed at body of stomach in control group and non-tumorous area of body in gastric cancer group. If gastric body area could not feasible (eg. tumor involvement), then gastric antrum and more proximal part of body will be sampling.

Intervention type: DIAGNOSTIC_TEST
Intervention: Gastric mucosal brushing
Description: Gastric mucosal brushing will be performed at body of stomach in control group and non-tumorous area of body in gastric cancer group. If gastric body area could not feasible (eg. tumor involvement), then gastric antrum and more proximal part of body will be sampling.

Intervention type: DIAGNOSTIC_TEST
Intervention: Gastric mucosal biopsy
Description: Gastric mucosal biopsy will be performed at the area within 2 cm. from brushing site.

Intervention type: DIAGNOSTIC_TEST
Intervention: Gastric mucosal biopsy
Description: Gastric mucosal biopsy will be performed at the area within 2 cm. from brushing site.
Study: NCT05893862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet
Study: NCT06410651

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nimotuzumab with chemoradiotherapy
Description: Radiotherapy, 40-50.4Gy/20-28f. Nimotuzumab 400mg, ivgtt, W2d. Chemotherapy, S-1, 40-60mg/m2, on BSA，orally twice daily on radiotherapy days.
Study: NCT05210439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short-treatment of any active antibiotic regimen
Description: 7 days of any active antibiotic treatment for BSI-PA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long-treatment of any active antibiotic regimen
Description: 14 days of any active antibiotic treatment for BSI-PA
Study: NCT04751760

Intervention type: BIOLOGICAL
Intervention: collection of blood and urine
Description: blood and urine will be collected during a blood test scheduled for the follow-up of the patient
Study: NCT05208996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: siCoV/KK46
Description: The modified phase I 3 + 1+1 study design was used in dose escalation from low dose to high dose to determine the maximum daily dose. Sequential assignment of Patient cohorts to one of three dose levels of inhaled siCoV/KK46: 3.7 mg, 11.1 mg, 22.2 mg.
Study: NCT06331390

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: nothing
Study: NCT05252741

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: serum samples and punch skin biopsies
Description: we will take serum samples from psoriasis patients and healthy controls and skin punch biopsies from lesional and non-lesional areas in psoriasis patients.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: serum samples and punch skin biopsies
Description: we will take serum samples from psoriasis patients and healthy controls and skin punch biopsies from lesional and non-lesional areas in psoriasis patients.
Study: NCT06145126

Intervention type: OTHER
Group type: OTHER
Intervention: Prednisolone
Description: Predisolone is used as a tool to elicit a physiological response (toolbox trial) and not as a pharmaceutical agent/treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: Prednisolone
Description: Predisolone is used as a tool to elicit a physiological response (toolbox trial) and not as a pharmaceutical agent/treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo to predinisolon

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo to predinisolon
Study: NCT06135740

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit wearing, with notification for sleep, activity and nutrition based fitbit data
Description: Notification on Nutrition, Sleep, and Physical Activity based on fitbit-based data, and Nutritional supplementation and Promotion of Exercise

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Routine care
Description: Regular Care on sleep, activity and nutrition
Study: NCT03705598

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Light physical exercise
Description: One hour each session, two sessions each week, for 24 weeks. Each session will be structured into three 15-minute segments (including warm-up activities/balance exercise/walking, upper and lower body strength exercise/walking, and stretching exercise/balance exercise/walking, respectively), each ending with a short break to record the Borg Rating of Perceived Exertion (RPE), followed by a 5-minute break time or cool-down/wrap-up session. The session will be taught by a certified exercise physiologist and a research assistant.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tai Chi
Description: One hour each session, two sessions each week, for 24 weeks. Each session will be structured into three 15-minute segments (including warm-up activities/balance exercise/breathing exercise, Tai Chi walking drills, and Tai Chi 8-form, respectively), each ending with a short break to record the RPE, and followed by a 5-minute break or cool-down/wrap-up session. The session will be taught by an experienced Tai Chi instructor and a research assistant.
Study: NCT05892705

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine Injection [Precedex]
Description: intrathecal injection of 5 mcg dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Injection [Precedex]
Description: intrathecal injection of 5 mcg dexmedetomidine
Study: NCT06311058

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein isolate
Description: 25g of whey protein isolate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein isolate
Description: 25g of whey protein isolate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein + BAA
Description: * Protein drink - 25g of whey protein isolate~* Amino Acid Blend - 7g of protein (4g Leucine, 1g iso leucine, 1g valine, 1g arginine)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: • isocaloric-matched (25g) maltodextrin supplement
Study: NCT05316064

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: probiotic
Description: oral administration of probiotic at 9 log CFU/day for 12 weeks to reduce vaginal abundance of HPV in women compared to placebo via the use of vaginal self-swab.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration of primarily carrier without the probiotic for 12 weeks
Study: NCT05943353

Intervention type: OTHER
Group type: OTHER
Intervention: Pentoxifylline
Description: Prominently, Pentoxyfilline (PTX) is a methylxanthine derivative, is an inhibitor of phosphodiesterase activity and increases intracellular cAMP levels, which play an important role in sperm motility. The ability of PTX to improve sperm motility was first recognized in the study of Turner et al (1978). One of the advantages of PTX is that it significantly reduces the time to find and select motile sperm in cases of completely immotile sperm. In recent years, many studies have demonstrated the effectiveness of PTX for the group of spermatozoa, sperm carrying severe abnormalities. Therefore, the use of a sperm motility inducer such as PTX is a potential method to replace traditional ICSI sperm selection methods. Therefore, we performed this study with the aim to evaluate the effectiveness of PTX to select sperm in ICSI on the group of sperm that were completely immotile after ejaculation and obtained from the procedure.
Study: NCT05852093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib+Buprenorphine Transdermal Patch
Description: NSAIDs+narcotic analgesics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib+Buprenorphine Transdermal Patch+Tizanidine
Description: NSAIDs+narcotic analgesics+Skeletal Muscle Relaxant
Study: NCT05311826

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: STANDARD PHYSIOTHERAPY TREATMENT
Description: The standard postoperative rehabilitation process starts from the first postoperative day. Two sessions are provided daily, with the exception of Sunday and Saturday afternoon. A single physiotherapy session, lasting 30 minutes, can include bed exercises for upper and lower limbs and recovery of autonomy (sitting position, standing and ambulation). In this phase, the sessions are characterized by educational and counseling activities.~The patient will be encouraged to carry out the activities independently.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EXPERIMENTAL diaphragmatic breathing exercise
Description: The subjects in the intervention group (EXP) will receive, in addition to standard physiotherapy treatment, diaphragmatic breathing exercise. Four exercises in different position (supine and side lying) will be provided for each physiotherapy session by a senior physiotherapist. Patients will be instructed to perform the same exercises independently to achieve relaxation and relief of pain symptoms.
Study: NCT04608331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours. The pump is established with morphine (0.5 mg/ml) and dexmedetomidine (1.25 microgram/ml), in a total volume of 160 ml normal saline, and programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate of 1 ml/h.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours. The pump is established with morphine (0.5 mg/ml), in a total volume of 160 ml normal saline, and programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate of 1 ml/h.
Study: NCT06487962

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM Intervention
Description: The intervention has 4 components with CGM uptake and maintenance as a primary focus. (1) Participants will visit their primary care provider (PCP) at baseline and 3- and 6-months post-baseline (or more frequently as needed) for review of CGM data and insulin therapy adjustments as indicated. Intervention providers received rigorous training in T1D management and CGM via Project ECHO (Extension for Community Healthcare Outcomes). (2) After each PCP visit, the CDCES will follow-up with participants to ensure participant understanding of the education/instructions provided at the PCP visit. (3) Next, participants will receive 4-weekly sessions of culturally sensitive, intensive CGM education and training led by a CDCES with accompaniment of a supportive family member or friend. (4) Virtual group support sessions, led by a peer educator, will follow over 5 months. During this period, the peer-led sessions will take place every two weeks and then move to every three weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: SMBG Control Condition
Description: The SMBG control condition consists of 3 components delivered over 6 months. (1) Participants will visit their PCP at baseline and 3- and 6-months post-baseline (or more frequently as needed) for review of SMBG data and insulin therapy adjustments as indicated. Control providers received rigorous training in T1D management via Project ECHO. (2) Commencing after the first PCP visit, participants will have 4-weekly telehealth visits for knowledge and skills reinforcement for SMBG. (3) CDCES support phone calls will follow over 5 months. During this period, the support phone calls will take place every two weeks and then move to every three weeks.
Study: NCT05104203

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracolumbar Interfascial Plane block
Description: Interfascial block done by injection between m. multifidus and m. longissimus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracolumbar Interfascial Plane block
Description: Interfascial block done by injection between m. multifidus and m. longissimus

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Thorcolumbar Interfascial Plane block
Description: Injection of local anesthetics between m. longissimus and m. illiocostalis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Thorcolumbar Interfascial Plane block
Description: Injection of local anesthetics between m. longissimus and m. illiocostalis
Study: NCT06378684

Intervention type: DRUG
Group type: OTHER
Intervention: Group 1: JW0104(Period 1), C2207(Period 2), JW0104 + C2207(Period 3)
Description: Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration

Intervention type: DRUG
Group type: OTHER
Intervention: Group 2: JW0104 + C2207(Period 1), JW0104(Period 2), C2207(Period 3)
Description: Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration

Intervention type: DRUG
Group type: OTHER
Intervention: Group 3: C2207(Period 1), JW0104 + C2207(Period 2), JW0104(Period 3)
Description: Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration

Intervention type: DRUG
Group type: OTHER
Intervention: Group 4: JW0104(Period 1), JW0104 + C2207(Period 2), C2207(Period 3)
Description: Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration

Intervention type: DRUG
Group type: OTHER
Intervention: Group 5: JW0104 + C2207(Period 1), C2207(Period 2), JW0104(Period 3)
Description: Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration

Intervention type: DRUG
Group type: OTHER
Intervention: Group 6: C2207(Period 1), JW0104(Period 2), JW0104 + C2207(Period 3)
Description: Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration
Study: NCT05701878

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMARTest mobile app for COVID-19 self-testing
Description: The mobile app has self-testing features and information with regard to self-testing and COVID-19.
Study: NCT05905159

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABM
Description: Direct attention away from pain-related information (i.e., facial expressions) through implicit training procedures

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Direct attention equally towards pain-related and neutral information (i.e., facial expressions) through implicit training procedures
Study: NCT06608121

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper limb isokinetic forces measurements
Description: The trial is a single-center prospective interventional study. Patients aged 18 to 85 years hospitalized in a French rehabilitation center for stroke, multiple sclerosis or traumatic tetraplegia and presenting a motor deficit ≤3/5 at the shoulder and elbow will be included. MVF measurements will be performed using an isokinetic ergometer during a single session. Concentric and eccentric MVF, as well as the forces generated during passive motion, will be measured in shoulder external-internal rotation and in elbow flexion-extension, in the seated position. The demographic, anthropometric and medical data required for the study will be extracted from medical records. Patients' residual muscle strength will be described and modeled. Explanatory factors for model quality will be determined.
Study: NCT06607900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hUC-MSC-sEV-001 nasal drops
Description: hUC-MSC-sEV-001 nasal drops
Study: NCT05401721

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum copeptin
Description: Blood test

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum copeptin
Description: Blood test
Study: NCT06064019

Intervention type: DEVICE
Group type: OTHER
Intervention: Nevisense
Description: The Nevisense system is based on Electrical Impedance Spectroscopy (EIS). EIS is a measure of the overall resistance within a skin tissue, at alternating currents of various frequencies. Since skin tissues have different electrical properties depending on cell structure and medical conditions, the resulting electrical impedance spectra will reflect the properties of the skin tissue.
Study: NCT05842499

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Line Set Strategy
Description: Substrate-guided ablation procedure of atypical atrial flutter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional strategy
Description: Electrical activation-guided ablation
Study: NCT06176976

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lugol's iodine solution 5%
Description: 4 drops of LS every 8 hours for 10 days preoperatively will be given
Study: NCT05846958

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser acupuncture
Description: Each patient in experimental group will receive laser acupuncture for 10 s with at least 4J/point for each point.10 minutes, three times per week for 4 weeks (total of 12 sessions)~nieght splint for 4 weeks .

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: night splint
Description: wearing night splint for 4 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: night splint
Description: wearing night splint for 4 weeks
Study: NCT05308966

Intervention type: OTHER
Intervention: Data collection
Description: Observational study without intervention except retrospective and prospective data collection : Patient characteristics, MPM characteristics, Treatment characteristics, Disease progression, Rebiopsy, Post treatments, Adverse events, Date and cause of death, Date of last news ; recorded in electronic case-report forms (eCRF).